MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Rhea-AI Summary

MediWound (Nasdaq: MDWD) announced peer-reviewed prospective clinical data showing NexoBrid substantially reduces embedded particles that cause traumatic tattoos after abrasion and blast injuries.

In a 15-patient study at Sheba Medical Center, mean pigmented wound area fell from 37.5% post-scrubbing to 2.1% after NexoBrid, a 92.5% reduction. Removal rates were 96% for abrasive injuries and 84% for explosive injuries. Treatments were bedside, well tolerated, and reported no treatment-related adverse events in the early post-procedure period.

Positive

• Pigmented area −92.5% (37.5% to 2.1%) after NexoBrid
• Abrasive injuries −96% visible pigment removal
• Explosive injuries −84% pigment reduction
• No treatment-related adverse events reported in early post-procedure period

Negative

• Small study size: 15 patients only
• Residual deep debris may remain after treatment in explosive injuries

Key Figures

Patients enrolled 15 patients Prospective traumatic tattoo study at Sheba Medical Center

Baseline pigmented area 37.5% Mean pigmented wound area before NexoBrid after mechanical scrubbing

Post-treatment pigmented area 2.1% Mean pigmented wound area immediately after NexoBrid treatment

Pigmented area reduction 92.5% Reduction in pigmented wound surface vs post-scrubbing baseline

Abrasive injury clearance 96% Average removal of visible pigments in abrasive injuries

Explosive injury clearance 84% Reduction of pigment load in explosive injuries

Treatment window Within 24 hours Timing of NexoBrid application after injury

Short interest days to cover 8.15 days Days to cover based on reported short data

Market Reality Check

$19.05 Last Close

Volume Volume 65,378 vs 88,891 20-day average (relative volume 0.74x) ahead of this clinical update. normal

Technical Price $18.47 is slightly above the $18.31 200-day moving average, indicating a trend near long-term support/resistance.

Peers on Argus

Peers show mixed moves, with HRTX -1.48%, NTHI -2.40%, TLSA +2.98%, TNYA +1.44%, TRDA -4.08%. MDWD’s modest -0.22% change appears company-specific rather than part of a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 20	Q3 earnings update	Positive	-5.6%	Q3 2025 revenue growth, cash position, and manufacturing expansion update.
Nov 05	Earnings scheduling	Neutral	+1.4%	Announcement of timing and access details for Q3 2025 results call.
Nov 03	Plant commissioning	Positive	-0.1%	Completion of expanded NexoBrid GMP facility targeting sixfold capacity boost.
Sep 29	Equity offering	Negative	+0.5%	$30M registered direct share offering to fund EscharEx and capacity.
Sep 25	Regulatory approval	Positive	-1.8%	Australian TGA marketing approval expanding NexoBrid to 45 countries.

Pattern Detected

Recent news, even when operationally positive, has often been met with flat or negative price reactions, suggesting cautious market sentiment toward updates.

Recent Company History

Over the last few months, MediWound has combined financing, manufacturing expansion, and geographic growth with steady clinical advancement. A $30M registered direct offering in late September 2025 funded EscharEx pre-commercial efforts and capacity build-out. NexoBrid gained approval in Australia, extending reach to 45 countries, and the expanded GMP facility commissioning targeted a sixfold production increase. Q3 2025 results showed revenue of $5.4M, up 23% year-over-year. Today’s NexoBrid clinical data adds to this trajectory of building evidence and commercial readiness.

Market Pulse Summary

This announcement highlights new peer-reviewed data for NexoBrid, showing a reduction in pigmented wound surface from 37.5% to 2.1% and high pigment clearance in both abrasive and blast injuries, with no reported treatment-related adverse events in 15 patients. In context of earlier NexoBrid and EscharEx clinical publications, it adds to the company’s evidence base. Investors may track future studies, real-world adoption, and any regulatory or label implications.

Key Terms

enzymatic therapeutics medical

"a global leader in next-generation enzymatic therapeutics for tissue repair"

Enzymatic therapeutics are medicines that use specific proteins called enzymes to correct, replace, or break down molecules that cause disease, like sending a specialized tool into a factory to fix or remove a faulty part. For investors, they matter because they can offer targeted, often first-in-class treatments with distinct regulatory and manufacturing challenges that affect development cost, approval risk, intellectual property value and potential market size.

traumatic tattoos medical

"demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion"

Traumatic tattoos are permanent skin discolorations that occur when dirt, metal, or other particles become embedded under the skin during an injury, much like grit left under a rug that can’t be swept away. For investors, they matter because they create demand for medical treatments, removal technologies and cosmetic services, can influence healthcare costs and liability risk, and therefore affect companies in dermatology, medical devices and aesthetic markets.

enzymatic debridement medical

"Enzymatic Bromelain-based Debridement with NexoBrid®: A New Treatment"

Enzymatic debridement is a medical method that uses specially formulated enzymes to dissolve and remove dead or damaged tissue from wounds without cutting. For investors, it signals a less invasive treatment option with potential advantages in safety, speed of recovery, and cost compared with surgical removal, so market adoption, regulatory clearance, and clinical results can meaningfully affect sales prospects and valuation — like a targeted cleaner that avoids needing a full renovation.

bromelain-based medical

"Enzymatic Bromelain-based Debridement with NexoBrid®"

Bromelain-based describes a product, drug or therapy that uses bromelain—an enzyme extracted from pineapples—as its main active ingredient. Think of it as a recipe where bromelain is the key spice that gives the product its effect. Investors care because the ingredient drives claims, regulatory review, manufacturing and sourcing risks, and market appeal tied to safety, clinical evidence and patent or supply advantages.

procedural sedation medical

"patients were treated with NexoBrid within 24 hours of injury under procedural sedation"

Procedural sedation is the controlled use of medicines to relax a patient and reduce pain or anxiety during a medical procedure while the patient remains able to breathe on their own, rather than being fully put to sleep. Investors care because it drives demand for sedative drugs, monitoring equipment, and training, and it can enable more procedures to be done safely and efficiently — like using a dimmer switch to make a task easier without turning the lights off entirely.

shrapnel medical

"glass, or metallic particles (shrapnel) into the skin"

Shrapnel is the broken metal, fragments and debris thrown outward when something explodes or ruptures, similar to small pieces flying off a shattered windshield after a crash. For investors it signals potential human injury, property damage, regulatory investigations, cleanup and legal or insurance costs that can hurt a company’s finances, operations and reputation, much like unexpected rubble slowing or stopping a construction project.

AI-generated analysis. Not financial advice.

MediWound Reports New Clinical Data Demonstrating NexoBrid^®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Prospective clinical data show NexoBrid^® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90%

Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further evaluation in acute trauma settings

YAVNE, Israel, December 10, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the peer-reviewed publication of new prospective clinical data showing that NexoBrid^® substantially reduces embedded particles associated with traumatic tattoos following abrasion and blast injuries.

Traumatic tattoos occur when high-velocity accidents or blasts drive materials such as asphalt, dirt, glass, or metallic particles (shrapnel) into the skin, often leaving not only permanent dark discoloration but also causing aesthetic deformities, functional impairment, and increased risk of inflammation or infection. Current standard of care relies on aggressive non-selective mechanical scrubbing, which may leave embedded particles behind and may risk damage to viable tissue.

The study is published in the Journal of Burn Care & Research, the official journal of the American Burn Association, under the title “Enzymatic Bromelain-based Debridement with NexoBrid^®: A New Treatment to Effectively Prevent Traumatic Tattoos After Abrasive Incidents and Explosive Events.”

In this prospective independent study, conducted at Sheba Medical Center’s National Burn Center, 15 patients diagnosed with traumatic tattoos resulting from friction or blast injuries underwent standard mechanical scrubbing to remove loose debris. Residual pigment load was then documented, and patients were treated with NexoBrid within 24 hours of injury under procedural sedation. Pigmentation was reassessed immediately after enzymatic debridement, using computer-based image analysis.

The mean pigmented wound area decreased from 37.5% before NexoBrid application to 2.1% afterward, a 92.5% reduction in pigmented wound surface compared with the post-scrubbing baseline, with every patient showing substantial clearance of foreign particles. In abrasive injuries, an average of 96% of visible pigments were removed, while pigment load in explosive injuries was reduced by 84%. Treatment was well tolerated, performed at bedside, and no treatment-related adverse events were reported during the early post-procedure period.

“In blast injuries and friction burns, where wound depth is highly irregular, NexoBrid provides the precision these cases demand,” said Professor Josef Haik, MD, MPH, Director of the Department of Plastic and Reconstructive Surgery and Burn Center at Sheba Medical Center. “We believe the effectiveness of NexoBrid is driven by its selective enzymatic action on damaged skin layers, which helps remove many of the particles embedded within them. In high-energy explosions, some debris may remain lodged in deeper tissues, yet NexoBrid consistently reveals a clean, well-defined wound bed, enabling clinicians to determine the most appropriate next steps.”

About the Study

The single center prospective study was conducted at Sheba National Burn Center and included 15 children and adults (aged 4–51 years) with traumatic tattoos following road accidents and explosive events. After initial scrubbing, NexoBrid was applied in a 1–3 mm layer to affected areas under occlusion for four hours and then removed, followed by repeated gentle scrubbing to reveal a clean wound bed.

Pigment reduction was quantified using ImageJ software by comparing pre- and post-treatment photographs. The authors report that this is the first published series to specifically evaluate enzymatic debridement with NexoBrid for the prevention of traumatic tattoos.

The investigators highlight the small sample size and short follow-up as limitations and call for larger, controlled studies to confirm the impact of NexoBrid on long-term cosmetic outcomes and to further explore combined approaches in complex trauma injuries.

About NexoBrid^®

NexoBrid^® is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.

NexoBrid development has been supported with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

Cautionary Note Regarding Forward-Looking Statements

MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products, including NexoBrid^® and product candidates. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.

These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 19, 2025 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

MediWound Contacts:
Hani Luxenburg         Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

FAQ

What clinical results did MediWound (MDWD) report for NexoBrid on December 10, 2025?

A prospective 15-patient study reported mean pigmented wound area dropped from 37.5% to 2.1% after NexoBrid, a 92.5% reduction.

How effective was NexoBrid for abrasive versus explosive traumatic tattoos in the MDWD study?

The study found 96% pigment removal in abrasive injuries and 84% reduction in explosive injuries.

Were there safety issues reported with NexoBrid in the traumatic tattoo study for MDWD?

No treatment-related adverse events were reported during the early post-procedure period.

How soon after injury was NexoBrid applied in the MDWD clinical study?

Patients were treated with NexoBrid within 24 hours of injury under procedural sedation.

Where was the NexoBrid traumatic tattoo study for MDWD conducted?

The prospective study was conducted at Sheba Medical Center’s National Burn Center and published in the Journal of Burn Care & Research.

What are the limitations of the December 10, 2025 MDWD NexoBrid study?

The study included only 15 patients and authors note some debris can remain lodged in deeper tissues after high-energy explosions.